by
According to a research report “Ear Nose Throat (ENT) Treatment Market (By Devices: Hearing Aid Devices, Voice Prosthesis, Nasal Splints, Hearing Implants, Endoscopes, Others; By Drug Type: Antibiotics, Antihistamines, Steroids, Anti-inflammatory Drugs, Others; By Organ Type: Ear, Nose, Throat; By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings, Others) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022 – 2030″ published by Precedence Research, the ear nose throat treatment market is projected to grow from USD 17.16 billion in 2022 and is forecasted to reach USD 27.95 billion by 2030; it is expected to grow at a CAGR of 8.4 % from 2021 to 2030.
The study provides an analysis of the period 2017-2030, wherein 2021 to 2030 is the forecast period and 2021 is considered as the base year.
Eyes, nose, and throat are referred to as ENT. An ear nose throat (ENT) specialist’s job is to diagnose and treat any disease, infection, or discomfort involving these human body parts, as the name implies. The ear nose throat (ENT) treatment market’s devices are used for a variety of applications. Hearing impairments are typically treated with devices or additional supports such as hearing tubes; however, these impairments can occasionally necessitate surgery.
Get a Free Sample Copy of this Report with Global Industry Analysis @ https://www.precedenceresearch.com/sample/1534
Due to the rising prevalence of ongoing infections and wounds, as well as the ageing population, the market for ear nose throat (ENT) treatment is growing rapidly. Screening devices and endoscopes can be used to diagnose ear nose throat (ENT) illnesses. The rising elderly population, rising prevalence of ear nose throat (ENT)-related illnesses, and rising adoption of less invasive ear nose throat (ENT) operations are some of the significant market drivers of the ear nose throat (ENT) treatment market.
Ear nose throat (ENT) diseases are serious health problems that come at a great financial and societal consequence. Hearing loss in newborns and youngsters obstructs the development of formative dialect and instructional progress. Adults have difficulties in their work and social lives as well as social rejection. Hearing loss can be caused by a variety of things such as childhood infections like mumps, measles, chronic otitis, congenital abnormalities, genetic diseases, and perinatal problems. The increased prevalence of ear nose throat (ENT) problems has been documented more frequently in recent years, resulting the expansion of the global ear nose throat (ENT) treatment market over the projection period.
Table of Contents
Scope of the ENT Treatment Market
| Report Coverage | Details |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Segments Covered | Devices, Drug Type, Organ Type, End User, Region |
Market Estimations Y-O-Y:
-
Market Size Was Valued In 2021: US$ 16.15 Billion
-
Market Size Is Projected to Grow By 2022: US$ 17.16 Billion
-
Market Size Is Projected to Grow By 2023: US$ 18.23 Billion
-
Market Size Is Projected to Grow By 2024: US$ 19.37 Billion
-
Market Size Is Projected to Grow By 2025: US$ 20.59 Billion
-
Market Size Is Projected to Grow By 2026: US$ 21.88 Billion
-
Market Size Is Projected to Grow By 2027: US$ 23.26 Billion
-
Market Size Is Projected to Grow By 2028: US$ 24.73 Billion
-
Market Size Is Projected to Grow By 2029: US$ 26.29 Billion
-
Market Size Is Projected to Grow By 2030: US$ 27.95 Billion
-
Compound Annual Growth Rate (CAGR) from 2022 to 2030: 6.3 percent
Report Highlights:
- Based on the devices, the hearing aid devicessegment dominated the global ear nose throat (ENT) treatment market in 2020 with highest market share. Increased demand for hearing aids is responsible for the substantial proportion of the ear nose throat (ENT) treatment market. Hearing loss can result from changes in the neural connections from the ear to the brain as people age.
- North America is the largest segment for ear nose throat (ENT) treatment market in terms of region. This is due to growing advantageous reimbursement scenario for ear nose throat (ENT) treatments as well as strong presence of significant participants in this region. Furthermore, the ear nose throat (ENT) treatment market in the region is driven by rising awareness leading to recognition of ear nose throat (ENT) devices.
- Asia-Pacific region is the fastest growing region in the ear nose throat (ENT) treatment market. This is attributed to the increased knowledge of ear nose throat (ENT) devices, rising number of patients suffering from sinusitis, and an increase in the older population.
Future of Ear Nose Throat (ENT) Treatment Market
Despite the fact that many medical insurance companies do not fund cosmetic ear nose throat (ENT) operations, such as cosmetic rhinoplasty and otoplasty, there is a growing demand for these procedures. Some of the major factors encouraging people to spend for cosmetic ear nose throat (ENT) procedures to improve their appearance include technological advancements, less invasive procedures, higher popularity, safety, and accessibility of most cosmetic procedures, a rebounding economy, and rising disposable incomes in emerging economies. As a result, the rising demand for aesthetic ear nose throat (ENT) operations opens up a plethora of potential for the ear nose throat (ENT) devices market to expand in the upcoming years.
COVID-19 Impact Analysis:
- The COVID-19 pandemic had a substantial impact on hospital resources around the world.
- This has largely been accomplished by drastically lowering inpatient and outpatient services for various diseases as well as adopting infection prevention and control methods.
- The number of ear nose throat (ENT) diseases screening and diagnostic procedures dropped dramatically, with the pandemic affecting nations all over the globe.
Read Also: Stationary Energy Storage Market to Drive Growth 24.9% by 2030
Key Developments in the Marketplace:
- By building World of Hearing, a new hearing solution store in the Netherlands, Sonova Holding AG wants to expand its ENT product development and commercial manufacture in 2020. Hearing aid fittings can now be conducted remotely, thanks to new technology developed by Sonova Holding AG.
- In December 2015, Otonomy Inc. received FDA permission for the marketing of their new antibiotic OTIPRIO, which is used to treat young patients with bilateral otitis media.
- In September 2019, Cochlear Limited and GN Hearing teamed up with Google to introduce support for direct Bluetooth Low Energy streaming from Android devices to hearing aids.
- In March 2020, WS Audiology introduced WIDEX MOMENT, the first generation of natural-sounding hearing aids. This is achievable because to Widex’sZeroDelay Technology.
Why should you invest in this report?
If you are aiming to enter the global ear nose throat treatment market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for ear nose throat treatment are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the global ear nose throat (ENT) treatment market include:
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline Pharmaceuticals
- Teva Pharmaceuticals Industries Ltd.
- Sonova Holding AG
- Starkey Laboratories Inc.
- Siemens Healthcare
- Sonic Innovations Inc.
- American Hearing Systems Inc.
- Dr. Reddy’s Laboratories Ltd.
Segments Covered in the Report
ENT Treatment Market By Devices
- Hearing Aid Devices
- Voice Prosthesis
- Nasal Splints
- Hearing Implants
- Endoscopes
- Others
ENT Treatment Market By Devices By Drug Type
- Antibiotics
- Antihistamines
- Steroids
- Anti-inflammatory Drugs
- Others
ENT Treatment Market By Devices By Organ Type
- Ear
- Nose
- Throat
ENT Treatment Market By Devices By End User
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Home Care Settings
- Others
ENT Treatment Market By Devices By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Ear Nose Throat (ENT) Treatment Market
5.1. COVID-19 Landscape: Ear Nose Throat (ENT) Treatment Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Ear Nose Throat (ENT) Treatment Market, By Devices
8.1. Ear Nose Throat (ENT) Treatment Market, by Devices Type, 2021-2030
8.1.1. Hearing Aid Devices
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Voice Prosthesis
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Nasal Splints
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Hearing Implants
8.1.4.1. Market Revenue and Forecast (2019-2030)
8.1.5. Endoscopes
8.1.5.1. Market Revenue and Forecast (2019-2030)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Ear Nose Throat (ENT) Treatment Market, By Drug Type
9.1. Ear Nose Throat (ENT) Treatment Market, by Drug Type, 2021-2030
9.1.1. Antibiotics
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Antihistamines
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Steroids
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Anti-inflammatory Drugs
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Ear Nose Throat (ENT) Treatment Market, By Organ Type
10.1. Ear Nose Throat (ENT) Treatment Market, by Organ Type, 2021-2030
10.1.1. Ear
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Nose
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Throat
10.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Ear Nose Throat (ENT) Treatment Market, By End User
11.1. Ear Nose Throat (ENT) Treatment Market, by End User, 2021-2030
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast (2019-2030)
11.1.2. Clinics
11.1.2.1. Market Revenue and Forecast (2019-2030)
11.1.3. Ambulatory Surgical Centers
11.1.3.1. Market Revenue and Forecast (2019-2030)
11.1.4. Home Care Settings
11.1.4.1. Market Revenue and Forecast (2019-2030)
11.1.5. Others
11.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 12. Global Ear Nose Throat (ENT) Treatment Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Devices (2019-2030)
12.1.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.1.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.1.4. Market Revenue and Forecast, by End User (2019-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Devices (2019-2030)
12.1.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.1.5.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.1.5.4. Market Revenue and Forecast, by End User (2019-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Devices (2019-2030)
12.1.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.1.6.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.1.6.4. Market Revenue and Forecast, by End User (2019-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Devices (2019-2030)
12.2.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.2.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.2.4. Market Revenue and Forecast, by End User (2019-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Devices (2019-2030)
12.2.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.2.5.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.2.5.4. Market Revenue and Forecast, by End User (2019-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Devices (2019-2030)
12.2.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.2.6.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.2.6.4. Market Revenue and Forecast, by End User (2019-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Devices (2019-2030)
12.2.7.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.2.7.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.2.7.4. Market Revenue and Forecast, by End User (2019-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Devices (2019-2030)
12.2.8.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.2.8.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.2.8.4. Market Revenue and Forecast, by End User (2019-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Devices (2019-2030)
12.3.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.3.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.3.4. Market Revenue and Forecast, by End User (2019-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Devices (2019-2030)
12.3.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.3.5.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.3.5.4. Market Revenue and Forecast, by End User (2019-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Devices (2019-2030)
12.3.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.3.6.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.3.6.4. Market Revenue and Forecast, by End User (2019-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Devices (2019-2030)
12.3.7.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.3.7.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.3.7.4. Market Revenue and Forecast, by End User (2019-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Devices (2019-2030)
12.3.8.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.3.8.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.3.8.4. Market Revenue and Forecast, by End User (2019-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Devices (2019-2030)
12.4.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.4.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.4.4. Market Revenue and Forecast, by End User (2019-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Devices (2019-2030)
12.4.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.4.5.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.4.5.4. Market Revenue and Forecast, by End User (2019-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Devices (2019-2030)
12.4.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.4.6.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.4.6.4. Market Revenue and Forecast, by End User (2019-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Devices (2019-2030)
12.4.7.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.4.7.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.4.7.4. Market Revenue and Forecast, by End User (2019-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Devices (2019-2030)
12.4.8.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.4.8.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.4.8.4. Market Revenue and Forecast, by End User (2019-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Devices (2019-2030)
12.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.5.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.5.4. Market Revenue and Forecast, by End User (2019-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Devices (2019-2030)
12.5.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.5.5.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.5.5.4. Market Revenue and Forecast, by End User (2019-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Devices (2019-2030)
12.5.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)
12.5.6.3. Market Revenue and Forecast, by Organ Type (2019-2030)
12.5.6.4. Market Revenue and Forecast, by End User (2019-2030)
Chapter 13. Company Profiles
13.1. Novartis AG
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Pfizer Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. GlaxoSmithKline Pharmaceuticals
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Teva Pharmaceuticals Industries Ltd.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Sonova Holding AG
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Starkey Laboratories Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Siemens Healthcare
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Sonic Innovations Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. American Hearing Systems Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Dr. Reddy’s Laboratories Ltd.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1534
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
